Visit WTR Logo
Subscribe now

Life Sciences

Oblon rules roost once more as the US’s top patent prosecution outfit

We reveal which US law firms secured most grants for their clients in 2019 overall and by 10 industry categories, as well as the fastest growers

Oblon rules roost once more as the US’s top patent prosecution outfit
23 Jan 2020

Indian court sends conflicting signals in AstraZeneca disputes

The High Court of Delhi has taken inconsistent positions on issues of evergreening and genus/species patents in case that goes to heart of protections available to life sciences companies

23 Jan 2020

Vivo joins ranks of top Chinese patentees

Homegrown smartphone firm increasingly targeted by licensors has upped its research output in recent years

Latest

View all
21 Jan 2020

Four trends that will shape life sciences IP deal-making in 2020

After a record-breaking 2019, here are the key value-creation issues to look out for in the new decade Read more

16 Jan 2020

Breaking: EPO Board of Appeal upholds invalidation of Broad’s CRISPR-Cas9 patent

Surprise move means Enlarged Board will not now be asked to consider key questions that were referred to it yesterday Read more

16 Jan 2020

Viability of sham litigation suits on the line in AbbVie appeal

The award of $448 million in antitrust damages against the company in case brought by the Federal Trade Commission is also at stake. Read more

16 Jan 2020

What IP owners need to know about the US-China trade deal

There are significant gains for branded pharma in the agreement. But in several other areas, China has made commitments it already meets Read more

News

View all
4 Jan 2020

If you thought the last decade was one of big change in IP, you ain't seen nothing yet

Over the last 10 years US patent leadership waned while value creation strategies evolved; but the coming years look set to be dominated by commoditisation, politicisation and, above all else, big data and AI  Read more

19 Dec 2019

Federal Circuit ruling marks out dangers of doctrine of equivalents estoppel

The CAFC’s Pharma Tech decision provides a series of important pointers on how to avoid amendment-based and argument-based estoppel during prosecution Read more

5 Dec 2019

The search for the world's leading IP strategists is on

IAM is currently seeking nominations for individuals to be considered for the 2020 edition of the Strategy 300 - our unique guide to the men and women who excel in the creation of IP value Read more

25 Nov 2019

Three hidden issues that could affect your China IP transaction

Cross-border deals face regulatory risks that go beyond IP law Read more

Analysis

View all
15 Jan 2020

Updated: Broad Institute faces tough fight in CRISPR patent appeal hearing

Oral hearings before the EPO’s Boards of Appeal may have a big impact on the European Cas9 landscape Read more

13 Jan 2020

After SCOTUS denies cert in high profile 101 cases focus moves back to Congress

Decision not to hear Athena dispute will disappoint many, but may prove catalyst to reinvigorate stalled efforts to reform US patent eligibility regime Read more

10 Jan 2020

In case against Apple, more evidence of the IP hazards of convergence

Medtech leader Masimo accuses tech giant of patent infringement and trade secret theft Read more

10 Jan 2020

Everything you need to know about 2019 US district court patent litigation

Apple top defendant again; Eastern District of Texas loses further ground; and other key stats Read more

Insights

View all
29 Nov 2019

IP market news highlights

IAM’s biggest autumn reads Read more

24 May 2019

IP market news highlights

Some of the major news stories carried on the IAM platform from March to mid-May. Read more

1 Apr 2019

IP market news highlights

The big stories from the IAM platform in February and March. Read more

Trending

1

Breaking: EPO Board of Appeal upholds invalidation of Broad’s CRISPR-Cas9 patent

2

Updated: Broad Institute faces tough fight in CRISPR patent appeal hearing

3

What IP owners need to know about the US-China trade deal

4

After SCOTUS denies cert in high profile 101 cases focus moves back to Congress

5

Viability of sham litigation suits on the line in AbbVie appeal

We use cookies on www.iam-media.com. By using this site, you agree that we may store and access cookies on your device. For further information please read our cookie policy and our terms and conditions.